INTRODUCTION
Proinsulin, a precursor molecule in the biosynthesis of insulin was first described in 1967 (1) and subsequently confirmed (2) (3) (4) (5) . The molecular weight of porcine proinsulin is 9082 and it is convertible to desalanyl insulin by controlled tryptic digestion. Porcine (6) and bovine (7) proinsulin have been isolated, purified, and their amino acid structure defined. Observations with isolated rat islets (5) showing release of proinsulin into the incubation medium under physiologic and pharmacologic conditions leading to the release of insulin support the likelihood that proinsulin may appear in the circulation. Clark and Steiner in a prior publication reported such an in vitro action for glucose (8) . A "big insulin" in human and animal plasmas has been described (9) . Though not conclusively proven, it seems likely that this material is indeed proinsulin. Efforts to specifically identify and measure proinsulin in the plasma have been Received for publication 8 September 1969 and in revised form 16 October 1969. hampered by technical problems such as lack of human proinsulin standards and the likelihood that the antigenic "connecting peptide" of proinsulin is also in the circulation and must be differentiated from intact proinsulin (8) (9) (10) .
The observations cited above have provoked many questions concerning the potential role of proinsulin in normal and diabetic subjects. The published reports to date indicate the biological activity of proinsulin in vitro and in vivo is small (11-13) compared with insulin. Shaw and Chance (11) have concluded from in vitro studies with rat muscle and adipose tissue, that the major biologic effects noted are associated with the conversion of proinsulin to insulin. A recent report (14) casts some doubt that such conversion takes place in vivo. However, no other evidence for in vivo or in vitro conversion of proinsulin has thus far been reported This paper is concerned with the investigation of the biological activity of proinsulin in both in vivo and in vitro systems. Experiments were designed to determine whether conversion of proinsulin to smaller molecules is essential for biological activity. In addition, the possibility that proinsulin might function as a competitive inhibitor of insulin was studied. METHODS Porcine proinsulin was obtained from Eli Lilly & Co. 1 The material had been prepared according to the procedure of Chance, Ellis, and Bromer (6) . Biological activity was reported as 3.1 U/mg as measured by the mouse convulsion assay. Beef insulin, 5X recrystallized, was also obtained from Eli Lilly. The biological activity was 24.8 U/mg by mouse convulsion assay.
In order to assess the purity of the proinsulin preparations, particularly with regard to possible contamination with insulin, the following procedures were carried out. Proinsulin was subj ected to polyacrylamide electrophoresis at pH 8.6 as described by Davis (15) , but modified according to The Canal Company, Rockville, Md., Technical Bulletin, September 1968, to produce an 18% small pore gel. Proinsulin iodinated with l31I according to the method of Hunter and 'Thanks to Walter Shaw and to Elanco Products Co., a subsidiary of Eli Lilly.
Greenwood (16) was purified by column chromatography on Sephadex G-50, equilibrated in 1 M acetic acid. Tubes corresponding to the peak areas of the elution pattern were pooled and freeze dried. The iodinated proinsulin was then tested for purity by polyacrylamide electrophoresis. Finally, to insure that any small insulin contamination of proinsulin was inactivated, 0.65 mg proinsulin was subjected to reduction in 7 M urea and then reoxidation of disulfide bonds as described by Steiner and Clark (17) . Reoxidation was allowed to proceed for 48 hr. To assure the effectiveness of the reduction 1.0 mg of insulin was similarly treated. Both preparations were tested in vivo for hypoglycemic activity.
Assays in vivo of biological activity were carried out using normal male rats (Sprague-Dawley, 200-250 g). They were fasted overnight and then anesthetized with sodium amytal (40 mg/kg) for the assay. Specified amounts of proinsulin, insulin, combinations of the two, or reduced and reoxidized proinsulin and insulin were inj ected into the jugular vein. Samples for blood glucose (18) were taken from tail at 0, 30, 45, 60, 90, 120, and 180 min. Rats were maintained under amytal anesthesia and warm throughout the procedure. Hypophysectomized and adrenalectomized rats (100-200 g) were studied in the fed state. These rats were anesthetized with amytal (20 mg/kg). Five rats were used for each dose level in all groups. The control group was injected with 1 ml saline, the same volume being used for the administration of proinsulin and insulin. In addition to the above, the effects of Kunitz pancreatic trypsin inhibitor (KPTI), obtained from Worthington Biochemical Corporation, were investigated. Each rat received KPTI (10 mg/ kg) with and without proinsulin. In a few experiments KPTI (50 mg/kg) was used. Antitrypsin activity of KPTI was tested against TPCK-treated trypsin according to the method described by Laskowski (19) .
In order to determine whether proinsulin remains intact in the circulation or is degraded to insulin or intermediate forms, samples of proinsulin-'11 were injected intravenously into rats. At specified times aortic exsanguination was carried out. Samples were kept at 4°C and the plasma separated by centrifugation. Sephadex G-50 chromatography (in 1 M acetic acid at 4°C) was performed immediately. Tubes corresponding to the peak areas were then subjected to polyacrylamide-gel electrophoresis. The behavior of the injected proinsulin in the above systems was compared to uninjected iodinated proinsulin.
In vitro studies were conducted with paired rat hemidiaphragms (20) . Rats (150 g) were fasted overnight, decapitated, and the hemidiaphragms were removed. They were incubated in 2 ml Krebs-bicarbonate buffer, pH 7.6, containing 200 mg/100 ml gelatin and 200 mg/100 ml glucose for a period of 60 min at 37°C in an atmosphere of 95% oxygen-5% carbon dioxide. The effect of insulin or insulinlike materials was determined by measuring the glucose uptake from the medium (mg/gm wet weight per hr). The effect of proinsulin was compared with that of insulin. The combination of proinsulin and insulin was also studied. In addition, the effect of KPTI (200-400 jug/ml) on the response of the hemidiaphragm to proinsulin was also studied.
Proinsulin-311 was incubated for 1 hr in the presenc' of hemidiaphragms with and without KPTI. After incubation, the diaphragms were homogenized and the total number of counts associated with the tissue determined. The medium (2 cc) after purification on Sephadex columns was then subjected to polyacrylamide electrophoresis. Insulin-1"I was also studied in vitro.
RESULTS

Biological activity of proinsulin in vivo
Normal rats. Assuming a molecular weight of 9082 for proinsulin and 6000 for insulin, approximately equimolar solutions of each were prepared in 0.9% NaCl. (Table I) . These data suggest a recovery of proinsulin of greater than 50% with essentially total loss of insulin activity. This recovery of biological activity is similar to that observed using immunoreactivity as a measure of proinsulin recovery (17) and supports the concept that the biological activity observed with proinsulin was not due to an insulin contaminant.
Reexamination of this preparation of proinsulin on polyacrylamide gel after approximately 1 month of storage in the frozen state (1 mg/ml in 0.03 N HCI), revealed evidence of significant change (Fig. 2) . A second band was now apparent migrating in a position consistent with either an intermediate form of proinsulin (21) or possibly desamido proinsulin (22) and representing a 20% contamination by densitometry. As a result of these observations, all proinsulin preparations were monitored by polyacrylamide gels before use in any of the experiments herein reported. Biological activity of proinsulin in vitro *Paired rat hemidiaphragms were incubated with vary-*ing amounts of proinsulin, insulin, and combinations of the two, and glucose uptake by the tissue was measured (Table IV) . Proinsulin (0.166 itg/ml) had an insulinlike effect. This effect appeared to be roughly equivalent to 0.02 utg/ml of insulin (500 oU/ml) and comparable to the 8-fold bioactivity difference noted with mouse convulsion assay. The addition of 0.166 og/ml proinsu- Effect of KPTI on proinsulin action
In vivo experiments in normal rats revealed no inhibitory effect of KPTI on proinsulin action (Table V) . In three animals, as large a dose as 50 mg/kg of KPTI was similarly ineffective. Preparations, inactive in vivo, when tested with rat hemidiaphragms frequently proved to be capable of inhibiting the insulin-like action of proinsulin. Considerable variability of the inhibitory effect was observed which could not be correlated with antitrypsin activity (Table VI) . On gel electrophoresis, KPTI was not homogenous. Three protein bands could be identified.
Proinsulin conversion studies
In order to determine whether proinsulin is converted to insulin, a tracer amount of chromatographically separated 'I-labeled proinsulin was injected intravenously into rats (250-300 g). Three animals were bled at 15 min, three at 30 min, and one at 45 min after injection. At these times, significant hypoglycemia could be observed with the previously described doses of unlabeled proinsulin. 2 ml of plasma from each of these animals was chromatographed on Sephadex G-50 in 1 M acetic acid and the eluted material was counted. A small peak appeared in the void volume while a single major peak which eluted in a position consistent with unchanged proinsulin was found at 15, 30, and 45 min. (Fig. 4 A) . A single peak eluting in the proinsulin position was obtained (110,000 cpm; 61% recovery). No peaks in the insulin position could be seen. A small peak (I) eluting with -the void volume was obtained. The addition of these counts (I) to the tail portion of the elution (III) represented 7% of the total counts. KPTI showed no effect upon the elution pattern. Thus 93% of the proinsulin remained undegraded after 60 mi nof incubation with diaphragm. The single proinsulin peak, including fractions where insulin would chromatograph, was lyophilized and placed on polyacrylamide gel. No evidence for insulin nor an intermediate form of proinsulin was obtained. There was no effect of KPTI on the gel patterns (Fig. 5) . Insulin-"'I was also incubated with hemidiaphragms with and without KPTI as in the above experiment. Of the insulin-"'I added, a recovery of 64% of the counts was obtained in both experiments. 5% of the total counts were sequestered in the diaphragm in the presence of KPTI of which 1.8% was not precipitable with 10% trichloroacetic acid. In the absence of KPTI, 11% of counts were found in the tissue of wh ch 3.2% was not precipitable.
The Sephadex elution patterns of the two media are shown in Fig. 4 Thus, molecular conversion of proinsulin does not occur in the circulation and seems also not to take place in vitro where a "hypoglycemic" action is demonstrable.
The effect of KPTI on proinsulin action is not clarified by the data obtained. The observations of Shaw and Chance (11) are confirmed in part in that in vitro inhibition of proinsulin action was observed with KPTI. No in vivo inhibition could be found. Further,' KPTI had no effect on the degradation or polyacrylamide patterns of the labeled proinsulin incubated with diaphragm. The only positive observation made with KPTI indicated that it somewhat diminished the degra- for 60 min +KPTI (400 ,ug/ml). The incubation medium is shown after Sephadex chromatography, proinsulin peak lyophilization, and polyacrylamide-gel electrophoresis. The gel was cut in 3-mm sections (A-J) and the 'lI counts plotted. Proinsulin is intact and KPTI has no effect on the pattern.
umns must be used to ascertain whether proinsulin remains intact. Secondly, prolonged storage of proinsulin may result in "spontaneous" appearance of bands moving on polyacrylamide in the position of proinsulin intermediates or more probably desamido proinsulin as suggested by the reports on insulin (22) . As a result, any studies of proinsulin action require definition of the purity of the preparation.
Finally, the lack of effect of proinsulin on insulin action deserves mention. Since proinsulin does not compete with insulin and does not require conversion to insulin, it could be important in the pathophysiology of diabetes only if present in the plasma as the major "insulin" moiety. Thus far no such circumstance has been documented in diabetics, although it has been reported in patients with insulinoma (26) . More precise measurements of proinsulin and its connecting peptide in diabetics may clarify the problem.
